fludarabine
Showing 26 - 50 of 741
Non Hodgkin's Lymphoma Trial in Beijing (TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T),
Not yet recruiting
- Non Hodgkin's Lymphoma
- TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T)
- +2 more
-
Beijing, China
- +2 more
Aug 23, 2023
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Biphenotypic Acute Leukemia Trial in Tampa (Fludarabine, Melphalan, Total
Active, not recruiting
- Acute Myeloid Leukemia
- +17 more
- Fludarabine
- +2 more
-
Tampa, FloridaH. Lee Moffitt Cancer Center & Research Institute
Jan 10, 2023
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Trial in Nanjin (Orelabrutinib, Obinutuzumab, Fludarabine)
Recruiting
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Orelabrutinib
- +3 more
-
Nanjin, Jiangsu, ChinaDepartment of Haematology, the First Affiliated Hospital of Nanj
Apr 12, 2022
Non Hodgkin Lymphoma Trial in Cleveland (UF-KURE19 CAR-T cells, Fludarabine, Cyclophosphamide)
Recruiting
- Non Hodgkin Lymphoma
- UF-KURE19 CAR-T cells
- +2 more
-
Cleveland, Ohio
- +1 more
Nov 21, 2022
Hematologic Malignancies Trial in New York (Busulfan 3.2 mg/kg/day, Fludarabine, Melphalan)
Recruiting
- Hematologic Malignancies
- Busulfan 3.2 mg/kg/day
- +5 more
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Mar 14, 2022
Non-hodgkin Lymphoma,B Cell Trial in Beijing (Autologous CD19-STAR-T cell, Fludarabine, Cyclophosphamide)
Recruiting
- Non-hodgkin Lymphoma,B Cell
- Autologous CD19-STAR-T cell
- +2 more
-
Beijing, Beijing, China
- +1 more
Nov 21, 2022
Fludarabine Drug Exposure in Pediatric Bone Marrow
Completed
- Hematologic Malignancies
- +7 more
- Fludarabine
-
San Francisco, CaliforniaUniversity of California, San Francisco
Sep 27, 2021
Chronic Lymphocytic Leukemia Trial in Boston (IPI-145, Fludarabine, Cyclophosphamide)
Active, not recruiting
- Chronic Lymphocytic Leukemia
- IPI-145
- +3 more
-
Boston, Massachusetts
- +1 more
Mar 10, 2022
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Houston (procedure, drug, biological)
Recruiting
- Recurrent Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia
- Allogeneic Hematopoietic Stem Cell Transplantation
- +7 more
-
Houston, TexasM D Anderson Cancer Center
Aug 18, 2022
B-Lymphoid Malignancies, Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia Trial in Houston (Fludarabine,
Active, not recruiting
- B-Lymphoid Malignancies
- +3 more
- Fludarabine
- +4 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Aug 1, 2022
Leukemia, Juvenile Myelomonocytic, JMML, JCML Trial (Trametinib, Azacitidine, Fludarabine)
Not yet recruiting
- Leukemia, Juvenile Myelomonocytic
- +4 more
- Trametinib
- +3 more
- (no location specified)
May 4, 2023
Relapsed/Refractory B-Cell Lymphoma Trial (FT522, Rituximab, Cyclophosphamide)
Not yet recruiting
- Relapsed/Refractory B-Cell Lymphoma
- FT522
- +4 more
- (no location specified)
Jul 10, 2023
Relapsed/Refractory Large B-cell Lymphoma Trial (KITE-197, Cyclophosphamide, Fludarabine)
Not yet recruiting
- Relapsed/Refractory Large B-cell Lymphoma
- KITE-197
- +2 more
- (no location specified)
Oct 6, 2023
Hematologic Malignancies Trial in Chicago, New York (device, drug, radiation)
Recruiting
- Hematologic Malignancies
- CliniMACS® CD34 Reagent System
- +7 more
-
Chicago, Illinois
- +1 more
Sep 20, 2022
Chronic Lymphocytic Leukemia, Leukemia Trial in United States (Ibrutinib, Fludarabine, Cyclophosphamide)
Active, not recruiting
- Chronic Lymphocytic Leukemia
- Leukemia
- Ibrutinib
- +3 more
-
Coral Gables, Florida
- +8 more
Sep 28, 2022
Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Trial in Duarte (drug, other,
Recruiting
- Acute Lymphoblastic Leukemia
- +7 more
- Fludarabine
- +3 more
-
Duarte, CaliforniaCity of Hope Medical Center
Feb 17, 2022
Cutaneous T-cell Lymphoma, T-Prolymphocytic Leukemia, T-Large Granulocytic Leukemia Trial in Columbus (Romidepsin, Busulfan,
Recruiting
- Cutaneous T-cell Lymphoma
- +4 more
- Romidepsin
- +4 more
-
Columbus, OhioThe Ohio State University Cancer Center
Apr 18, 2022
Acute Myelogenous Leukemia, MDS, Mixed Phenotype Acute Leukemia Trial (Fludarabine, Cytarabine, Uproleselan)
Not yet recruiting
- Acute Myelogenous Leukemia
- +2 more
- Fludarabine
- +2 more
- (no location specified)
Mar 3, 2022
Sickle Cell Disease Trial in Hackensack (Alemtuzumab, Fludarabine, Melphalan)
Active, not recruiting
- Sickle Cell Disease
- Alemtuzumab
- +3 more
-
Hackensack, New JerseyHackensack University Medical Center
Feb 4, 2022
Myeloid Hematological Malignancies Trial in Houston (Busulfan, Cyclophosphamide, Fludarabine)
Completed
- Myeloid Hematological Malignancies
- Busulfan
- +3 more
-
Houston, TexasTexas Children's Hospital
May 13, 2022
Relapsed and/or Refractory Multiple Myeloma Trial in Köln (BMS-986453, Fludarabine, Cyclophosphamide)
Not yet recruiting
- Relapsed and/or Refractory Multiple Myeloma
- BMS-986453
- +2 more
-
Köln, GermanyLocal Institution - 0017
Dec 4, 2023
CD19-positive Relapsed or Refractory B-cell Malignancies Trial in Hefei (UTAA09 cells for infusion, Fludarabine,
Not yet recruiting
- CD19-positive Relapsed or Refractory B-cell Malignancies
- UTAA09 cells for infusion
- +2 more
-
Hefei, Anhui, ChinaThe First Affiliated Hospital of USTC (AnHui Provincial Hospital
Oct 13, 2023
Solid Tumor Trial (Tumor Infiltrating Lymphocytes, Fludarabine, Cyclophosphamide Capsules)
Not yet recruiting
- Solid Tumor
- Tumor Infiltrating Lymphocytes
- +3 more
- (no location specified)
Dec 11, 2022
Hepatocellular Carcinoma, Hepatocellular Cancer, Metastatic Hepatocellular Carcinoma Trial run by the NCI (Cyclophosphamide,
Recruiting
- Hepatocellular Carcinoma
- +2 more
- Cyclophosphamide
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 20, 2023